|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-8-13
|
|
pubmed:abstractText |
RNF (Rebif New Formulation, Merck Serono International S.A., Geneva, Switzerland), a formulation of interferon-beta1a (IFN-beta1a) without human- or animal-derived components, is currently under investigation. It was developed with the aim of maximizing the treatment benefit for patients with multiple sclerosis (MS) by improving injection tolerability and reducing the development of neutralizing antibodies (NAbs).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
pubmed-author:BarbarashOlgaO,
pubmed-author:Casset-SemanazFlorenceF,
pubmed-author:GiovannoniGavinG,
pubmed-author:KingJohnJ,
pubmed-author:MINESAA,
pubmed-author:MetzLuanneL,
pubmed-author:PardoGabrielG,
pubmed-author:RNF Study Group,
pubmed-author:SørensenPer SoelbergPS,
pubmed-author:SimsarianJamesJ,
pubmed-author:StubinskiBettinaB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1128-45
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17692727-Adolescent,
pubmed-meshheading:17692727-Adult,
pubmed-meshheading:17692727-Chemistry, Pharmaceutical,
pubmed-meshheading:17692727-Dose-Response Relationship, Drug,
pubmed-meshheading:17692727-Europe,
pubmed-meshheading:17692727-Female,
pubmed-meshheading:17692727-Humans,
pubmed-meshheading:17692727-Immunologic Factors,
pubmed-meshheading:17692727-Interferon-beta,
pubmed-meshheading:17692727-Male,
pubmed-meshheading:17692727-Middle Aged,
pubmed-meshheading:17692727-Multiple Sclerosis,
pubmed-meshheading:17692727-North America,
pubmed-meshheading:17692727-Prospective Studies,
pubmed-meshheading:17692727-Single-Blind Method,
pubmed-meshheading:17692727-Time Factors,
pubmed-meshheading:17692727-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
|
|
pubmed:affiliation |
Neuroimmunology Unit, Institute of Cell and Molecular Science, Queen Mary University London, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
